Pancreatic Ductal Adenocarcinoma Treatment

Pancreatic ductal adenocarcinoma (PDAC) may be treatable using newly-developed small molecules that show high antiproliferative activity against the pancreatic cancer cell line MiaPaca-2. This technology disrupts the mTOR and autophagy pathways, offering a new mechanism of action for treating pancreatic cancer. The molecules of interest have submicromolar activity, good metabolic stability in both plasma and liver microsomes, and have increased autophagy at the basal levels and reduced mTORC1 activity.

Disrupts mTOR and Autophagy Pathway

PDAC, one of the most lethal forms of cancer in the US, is commonly diagnosed in late stages and often resistant to “normal” cancer cell-killing methods such as apoptotic cell death, an established cancer cell-killing mechanism. Currently available treatments offer poor results with a five year survival rate of only around 5%. The newly-designed chemical structures in this technology show high antiproliferative activity in a pancreatic cancer cell line and propose a new method that disrupts mTOR and autophagy pathways. The treatment has shown high anticancer activity and good drug-like properties.

**BENEFITS AND FEATURES:**

- High antiproliferative activity against MiaPaca-2 pancreatic cancer cell line
- New mechanism of action disrupts mTOR and autophagy pathways
- Submicromolar activity
- Good metabolic stability in both plasma and liver microsomes

Learn about more groundbreaking discoveries at [www.research.umn.edu/techcomm](http://www.research.umn.edu/techcomm)
• Increased autophagy at the basal levels and reduced mTORC1 activity

APPLICATIONS:
• Pancreatic cancer treatment
• Modulating autophagy

Phase of Development - Lead optimization

Interested in Licensing?
The University relies on industry partners to scale up technologies to large enough production capacity for commercial purposes. The license is available for this technology and would be for the sale, manufacture or use of products claimed by the issued patents. Please contact Kevin Anderson to share your business needs and technical interest in this PDAC treatment technology and if you are interested in licensing the technology for further research and development.

Inventors
Liqiang Chen, PhD
Assistant Professor, Center for Drug Design (CODD)

IP: UM Docket 20160388

For additional information, contact
Kevin Anderson
Technology Licensing Officer
exprlic@umn.edu
612-624-8293

Learn about more groundbreaking discoveries at www.research.umn.edu/techcomm